Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989676 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29989746 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL13946516 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30082405 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL14940666 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29401317 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL2033787 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL5260936 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30229677 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL20299891 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192299-B | Zilucoplan preparation method | 杭州诺泰诺和生物医药科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119192299-A | Zilucoplan preparation method | 杭州诺泰诺和生物医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| EP-0531443-A4 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | — | 1993-04-21 | — | — | EP | claimed |
| EP-0531443-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-03-17 | — | — | EP | claimed |
| US-5079260-A | Side effect reduction; fluorene derivatives | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-07 | — | — | US | claimed |
| WO-1991018596-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | WEITZBERG MOSHE (US) | 1991-12-12 | — | — | WO | claimed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | BOARD OF REGENTS OF THE UNIVERISTY OF NEBRASKA (US) | 2025-12-02 | — | — | US | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0531443-A4 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | — | 1993-04-21 | — | — | EP | disclosed |
| EP-0531443-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5079260-A | Side effect reduction; fluorene derivatives | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-07 | — | — | US | disclosed |
| WO-1991018596-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | WEITZBERG MOSHE (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | CASP3 1956/4885MDM4 4858/4885TP53 1929/4885 |
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | FOLH1, SSTR4, SLC18A2 | CASP3 4331/4885MDM4 1938/4885TP53 531/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | CASP3 1560/4885MDM4 3040/4885TP53 421/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | CASP3 2990/4885MDM4 4213/4885TP53 135/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | CASP3 2720/4885MDM4 1761/4885TP53 630/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | CASP3 609/4885MDM4 2595/4885TP53 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.